New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
08:08 EDTACSTAcasti Pharma completes Phase II TRIFECTA, Pharmacokinetic trials
Acasti Pharma announces the completion of two trials, the Phase II double-blind, placebo-controlled, or TRIFECTA, study and the Pharmacokinetic trial. The primary objective of the TRIFECTA trial is to evaluate the safety and efficacy of CaPre in reducing triglyceride levels in patients with mild to severe hypertriglyceridemia. Given that the stopping threshold had been met, the data review committee members recommended that there was sufficient evidence of a treatment effect that warranted the termination of the study. The corporation intends to unblind the study and top-line results are expected by the end of September, with full data coming out in the following quarter. Acasti's Pharmacokinetic trial is designed to evaluate blood profiles and bioavailability in healthy human volunteers taking single and multiple doses of Capre. Top-line results are expected to be available by the end of September, with full data coming out in the following quarter.
News For ACST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ACST

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use